Literature DB >> 7911536

Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry.

P J Swart1, W E Oelen, A P Bruins, P G Tepper, R A de Zeeuw.   

Abstract

The metabolism of the dopamine D2 agonist N-0923 was investigated by an in vitro isolated liver perfusion. Determining the metabolic profile and identity of the different metabolites was achieved by using high-performance liquid chromatography with UV detection, combined with atmospheric pressure ionization mass spectrometry. Using this technique, no extensive sample cleanup is required, and the studies can be performed without radioactivity. In addition to previously observed metabolites, nine new metabolic products were identified. All metabolites were exclusively excreted into the bile, except for the despropyl metabolite, which was also detectable in the perfusate. 5-O-Glucuronidation and N-depropylation followed by 5-O-glucuronidation are the most important metabolic routes. N-dealkylation of the thienylethyl group followed by 5-O-glucuronidation and sulfation is a second major metabolic pathway. Catechol formation of the despropyl metabolite with or without subsequent conjugation was not found. Catechol formation of the desthienylethyl metabolite occurred, but only its glucuronide conjugates were found. This study complements previous results of in vivo metabolic studies using the radiolabeled racemate N-0437, and it explains differences in bile excretion during isolated liver perfusions using N-0923 and radiolabeled N-0923.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911536     DOI: 10.1093/jat/18.2.71

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  3 in total

1.  Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.

Authors:  Willi Cawello; Andreas Fichtner; Hilmar Boekens; Marina Braun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-09-20       Impact factor: 2.441

2.  Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial.

Authors:  Willi Cawello; Hans Michael Wolff; Wim J A Meuling; Rolf Horstmann; Marina Braun
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration.

Authors:  Akhmad Kharis Nugroho; Gai Ling Li; Meindert Danhof; Joke A Bouwstra
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.